Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Skeleton and Calcium Homeostasis01:21

Skeleton and Calcium Homeostasis

4.6K
Calcium is not only the most abundant mineral in bone but also the most abundant mineral in the human body. Calcium ions are needed for bone mineralization, tooth health, heart rate regulation and strength of contraction, blood coagulation, the contraction of smooth and skeletal muscle cells, and the regulation of nerve impulse conduction. The average calcium level in the blood is about 10 mg/dL. When the body cannot maintain this level, a person will experience hypo or hypercalcemia.
4.6K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

3.0K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

210
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
210
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

2.8K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
2.8K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

256
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
256

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer.

The Journal of clinical endocrinology and metabolism·2026
Same author

Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer.

JCO oncology practice·2025
Same author

Bone health in cancer: perspective on the use of osteoanabolic agents.

Therapeutic advances in endocrinology and metabolism·2025
Same author

Teriparatide as an adjuvant therapy in the management of advanced-stage medication-related osteonecrosis of the jaw.

Oral surgery, oral medicine, oral pathology and oral radiology·2025
Same author

A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.

Breast cancer research : BCR·2024
Same author

Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique.

NPJ breast cancer·2024

Related Experiment Video

Updated: Jul 28, 2025

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.4K

Refractory hypercalcemia of malignancy: a problem with many potential roots.

Azeez Farooki1,2

  • 1Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

Frontiers in Endocrinology
|June 2, 2023
PubMed
Summary

Refractory hypercalcemia of malignancy (HCM) poses challenges despite available treatments. This review covers HCM drivers, mechanisms, current therapies, and future directions for managing this complex condition.

Keywords:
PTHrP (parathyroid hormone-related protein)bone resorptionbone resorption and formationcalcitrioldenosumabhypercalcemia of malignancyhypercalciuriaintravenous bisphosphonates

More Related Videos

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation
08:05

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation

Published on: June 8, 2018

11.5K
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.2K

Related Experiment Videos

Last Updated: Jul 28, 2025

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.4K
A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation
08:05

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation

Published on: June 8, 2018

11.5K
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.2K

Area of Science:

  • Oncology
  • Endocrinology
  • Clinical Medicine

Background:

  • Hypercalcemia of malignancy (HCM) is a frequent complication of cancer, significantly impacting patient morbidity and quality of life.
  • Existing medical treatments for HCM are effective but may fail in refractory cases, necessitating alternative strategies.
  • Refractory HCM is defined by recurrent severe hypercalcemia shortly after hospital discharge despite standard therapies.

Purpose of the Study:

  • To elucidate the primary drivers and physiological mechanisms underlying hypercalcemia of malignancy.
  • To review current therapeutic options targeting specific contributory mechanisms of HCM.
  • To explore potential future treatments for refractory HCM requiring further investigation.

Main Methods:

  • Literature review and synthesis of existing research on HCM.
  • Analysis of pathophysiological pathways contributing to elevated serum calcium in cancer patients.
  • Discussion of established and emerging treatment modalities for HCM management.

Main Results:

  • HCM is driven by various factors, including humoral factors and bone metastases, which elevate serum calcium through distinct physiological pathways.
  • Current treatments, such as bisphosphonates and denosumab, target these mechanisms but may be insufficient for refractory cases.
  • Understanding the specific drivers of HCM allows for targeted therapeutic interventions.

Conclusions:

  • Effective management of refractory hypercalcemia of malignancy requires a thorough understanding of its underlying mechanisms.
  • A multi-faceted approach, combining existing therapies with novel treatments, is crucial for improving outcomes in patients with refractory HCM.
  • Further research into novel therapeutic targets is essential to address the unmet needs in managing this challenging oncological complication.